Wir sind mit live! Mehr erfahren
TNDM-Symbol

Tandem Diabetes Care

16,24 USD
-0,28
1,69 %
Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT
1 Tag
-1,69 %
5 Tage
0,81 %
1 Monat
-7,36 %
3 Monate
-0,31 %
6 Monate
-19,16 %
Seit Jahresbeginn
-24,64 %
1 Jahr
6,21 %
5 Jahre
-86,77 %
10 Jahre
-75,39 %
 

Profil: Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on the Sigi tubeless patch pump. Tandem is also developing a fully closed-loop algorithm for its pumps. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 3 to 7 days.

Mitarbeiter: 2.500

Nachrichten

Positiv
Neutral
Negativ
Stimmung 3 Monate
Positiv 35,7 %
Neutral 50 %
Negativ 14,3 %
Neutral
Zacks Investment Research
vor 7 Tagen
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Tandem Diabetes is advancing next-generation insulin delivery technology and international expansion, but competition and supply constraints pose challenges to growth.
Is it the Right Time to Hold TNDM Stock in Your Portfolio?
Neutral
Business Wire
vor 15 Tagen
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
SAN DIEGO--(BUSINESS WIRE)--Tandem Diabetes Care, Inc. (Nasdaq: TNDM), a leading insulin delivery and diabetes technology company, plans to release its third quarter 2026 results after the financial markets close on Thursday, November 5, 2026. The Company will hold a conference call and simultaneous webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to discuss its third quarter 2026 financial and operating results. A live webcast of the call will be available on Tandem Diab.
Tandem Diabetes Care to Announce Third Quarter 2026 Financial Results on November 5, 2026
Neutral
Business Wire
vor 18 Tagen
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
MILAN--(BUSINESS WIRE)---- $TNDM #T2D--The Tandem Mobi automated insulin delivery system with Control-IQ+ automated insulin delivery technology is now available in 12 international markets.
Tandem Mobi Automated Insulin Delivery System Now Available in Twelve International Markets
Positiv
Zacks Investment Research
vor 29 Tagen
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Tandem Diabetes Care (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
Tandem Diabetes Care (TNDM) Soars 7.7%: Is Further Upside Left in the Stock?
Neutral
Zacks Investment Research
letzten Monat
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
TNDM's expanding pump lineup and pay-as-you-go model support growth prospects, though macro and competitive pressures remain.
Reasons to Retain Tandem Diabetes Stock in Your Portfolio Now
Positiv
Benzinga
letzten Monat
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
On Friday, William Blair initiated coverage on Tandem Diabetes Care Inc. (NASDAQ:TNDM) and Beta Bionics Inc (NASDAQ:BBNX), noting that both companies are advancing initiatives to play in faster-growing segments of the insulin pump market.
Innovative Insulin Pumps Drive Optimism for Tandem, Beta Bionics
Positiv
MarketBeat
vor 2 Monaten
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Tandem Diabetes Care NASDAQ: TNDM highlighted its plans to expand insulin pump adoption through a shift to pharmacy distribution in the U.S., direct sales in additional international markets and upcoming product launches, including a tubeless version of its Tandem Mobi pump.
Tandem Diabetes Care Maps Growth Plan With Pharmacy Shift and Tubeless Mobi
Negativ
Zacks Investment Research
vor 2 Monaten
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Tandem Diabetes shares jump 19.1% after a narrower-than-expected Q2 loss, as higher pump shipments and a 57% gross margin offset a slight revenue miss.
TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up
Positiv
MarketBeat
vor 2 Monaten
Tandem Diabetes Care Q2 Earnings Call Highlights
Tandem Diabetes Care NASDAQ: TNDM reported second-quarter results that included record sales, pump shipments and gross margin for a second quarter, while management highlighted early progress in its transition to pharmacy-channel reimbursement and continued development of new insulin-delivery technologies.
Tandem Diabetes Care Q2 Earnings Call Highlights
Neutral
Seeking Alpha
vor 2 Monaten
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Tandem Diabetes Care, Inc. (TNDM) Q2 2026 Earnings Call Transcript
Kursdiagramme mit Lightweight Charts™ umgesetzt